[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rheumatic-heart-disease-in-children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rheumatic-heart-disease-in-children":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,54,89,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100054258","adapting-enhanced-supports-to-improve-patient-adherence-to-secondary-antibiotic-prophylaxis-for-rheumatic-heart-disease-100054258",false,"NCT07666048","Adapting Enhanced Supports to Improve Patient Adherence to Secondary Antibiotic Prophylaxis for Rheumatic Heart Disease","SHIELD 3 Adapt","Inclusion Criteria:\n\n* Adults living with rheumatic heart disease (RHD): age ≥18 years; diagnosed with RHD; prescribed secondary antibiotic prophylaxis (SAP)\n* Guardians of children living with RHD: age ≥18 years; caregiver\u002Fguardian of a child aged 5-17 years with diagnosed RHD who is prescribed SAP\n* Children living with RHD: age 12-17 years; diagnosed with RHD; prescribed SAP\n* Community health workers (CHWs): age ≥18 years; associated with a healthcare center providing care to patients with RHD\n* Healthcare workers (HCWs): age ≥18 years; employed at a healthcare center providing care to patients with RHD; able to provide informed consent in English or the local language\n\nExclusion Criteria:\n\n* Adults living with RHD: medical contraindication to SAP; inability to provide informed consent (e.g., significant cognitive or communication impairment precluding participation)\n* Guardians of children living with RHD: child has a medical contraindication to SAP; inability to provide informed consent\n* Children living with RHD: medical contraindication to SAP; inability to provide informed assent (e.g., significant cognitive or communication impairment precluding participation)\n* Community health workers: none\n* Healthcare workers: none","ALL",{"count":18,"type":19},308,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to test the effectiveness and implementation of enhanced Secondary Antibiotic Prophylaxis (SAP) supports using a hybrid type 1 effectiveness-implementation design. The purpose is to determine whether enhanced SAP supports will increase average SAP adherence in Brazil and Timor-Leste. The study will enroll people living with Rheumatic Heart Disease (RHD) and Community Health Workers (CHWs) participating in the intervention.\n\nThe main questions it aims to answer are:\n\n* Whether CHW-led supports delivered within the community improve mean SAP adherence at 12 months post-intervention.\n* Whether the intervention demonstrates acceptability, feasibility, uptake and engagement.\n\nResearchers will compare baseline and post-intervention SAP adherence data for the 12 months prior to and following intervention rollout to see if CHW-delivered supports increase adherence.",[23],"Rheumatic Heart Disease in Children",[25,26,27,28],"Secondary Antibiotic Prophylaxis for Rheumatic Heart Disease","SAP for RHD","SAP Adherence","Secondary Antibiotic Prophylaxis Adherence","NOT_YET_RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":19},"2026-08-01",{"date":37,"type":19},"2030-12-31",{"name":39,"class":40},"Children's Hospital Medical Center, Cincinnati","OTHER",1,{"id":43,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":44,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":45,"keywords":46,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":53,"locationsCount":41},"100644246",{"count":18,"type":19},[23],[25,26,27,28],"2026-06-18",{"date":49,"type":33},"2026-06-24",{"date":51,"type":19},"2026-06-01",{"date":37,"type":19},{"name":39,"class":40},{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":16,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100571439","school-based-program-for-the-prevention-of-rheumatic-heart-disease-in-endemic-regions-100571439","NCT06720272","School-based Program for the Prevention of Rheumatic Heart Disease in Endemic Regions","Effectiveness of an Integrated Program for the Prevention of Rheumatic Heart Disease in Endemic Regions: a Stepped Wedge Cluster Randomized Trial","PREVENT","Inclusion Criteria:\n\n\\- Children aged 5-16 years\n\nExclusion Criteria:\n\n* Children \u002F primary caregivers not providing informed consent to participate\n* Children not attending one of the selected schools",true,"5 Years","16 Years",{"count":66,"type":19},6000,"INTERVENTIONAL",[69],"NA","The overall objective of the PREVENT trial is to evaluate the effectiveness of an integrated, school-based program for the prevention of rheumatic heart disease (RHD) in regions with an endemic pattern of RHD.\n\nWe conduct a stepped wedge cluster randomized trial in randomly selected schools in Nepal and Zambia.\n\nThe intervention will be delivered at the level of the school and consists in the introduction of a dedicated school-nurse program providing health care through education about RHD, assessment, intervention, and follow-up of GABHS pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with RHD.",[23],[73,74,75,76,77],"rheumatic heart disease","valvular heart disease","prevention","streptococcal pharyngitis","rheumatic fever","RECRUITING","2026-01-16",{"date":81,"type":33},"2026-01-20",{"date":83,"type":33},"2024-12-15",{"date":85,"type":19},"2028-02",{"name":87,"class":40},"Thomas Pilgrim",2,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":62,"sex":16,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":67,"phases":101,"briefSummary":104,"conditions":105,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":41},"100598966","phase-1-clinical-trial-phase-iiia-to-evaluate-the-safety-and-immunogenicity-of-streptincor-100598966","NCT07078357","Clinical Trial Phase I\u002FIIa to Evaluate the Safety and Immunogenicity of StreptInCor","Phase I\u002FIIa Clinical Trial to Evaluate the Safety and Immunogenicity of StreptInCor, a Synthetic Vaccine Against Streptococcus Pyogenes, in Healthy Adult Volunteers.","StreptInCorVac","Inclusion Criteria:\n\n* • Healthy male or female volunteers, aged between 18 and 45 years;\n\n  * Availability to undergo all procedures throughout the study period;\n  * Provide free and informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Participation in clinical trials within the last year\n* Participation in cohort studies\n* Diagnosis of concomitant infections or diseases that may affect immunity, including active HIV infection, hepatitis B, hepatitis C, diabetes mellitus, neoplasms, and autoimmune diseases;\n* Current or previous diagnosis or family history of ARF, chorea, obsessive-compulsive disorder, or glomerulonephritis;\n* Current or previous diagnosis of heart diseases;\n* Severe asthma or chronic obstructive pulmonary disease (COPD);\n* Abnormal neurological clinical assessment, especially chorea;\n* Use of treatments that may affect immunity in the last four weeks, including immunomodulators, corticosteroids (only systemic use for two weeks or more), or antineoplastic agents;\n* Use of treatments that may affect heart valves in the last four weeks or planned during the study period, including fenfluramine and dexfenfluramine;\n* Renal insufficiency determined by estimated creatinine clearance below 45 ml\u002Fmin\u002F1.73m²;\n* History of intolerance or allergy to any component of the study product, including antigen or adjuvant;\n* Presence of valve abnormalities or alterations in cardiac anatomy as defined by echocardiogram;\n* Altered electrocardiogram;\n* Evidence or suspicion of recent S. pyogenes infection based on clinical symptoms in the last four weeks;\n* Pregnancy, breastfeeding mother, or intention to become pregnant during the study period (only female participants);\n* Any other condition that may interfere with the study process as assessed by the researchers, including sample size and statistical power.","18 Years","45 Years",{"count":100,"type":19},60,[102,103],"PHASE1","PHASE2","This is a Phase I\u002FIIa, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to test the candidate vaccine StreptInCor. The study will include four different doses (25 µg, 50 µg, 100 µg, and 200 µg) of StreptInCor produced under Good Manufacturing Practices (GMP) and formulated with aluminum hydroxide as the vaccine adjuvant. The adjuvant alone will be used as a placebo in this trial. Five groups, each consisting of twelve healthy adult volunteers, will randomly receive two doses of the vaccine or placebo with a 28-day interval, along with a booster dose six months after the initial vaccination",[106,23,107,108,109,110],"Rheumatic Heart Disease","Vaccine Adverse Reaction","Rheumatic Diseases","Vaccine Acceptance","Vaccine",[112,113,114,115,116],"Acute rheumatic fever","Rheumatic heart disease","Vaccine development program","Group A streptococcus (GAS)","Streptococcus pyogenes","2025-07-17",{"date":119,"type":33},"2025-07-22",{"date":121,"type":19},"2025-10-01",{"date":123,"type":19},"2028-12-01",{"name":125,"class":40},"University of Sao Paulo General Hospital",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":62,"sex":16,"minAge":63,"maxAge":64,"enrollmentInfo":134,"targetDuration":4,"studyType":67,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":41},"100478050","effectiveness-of-a-school-centered-prevention-program-on-prevalence-of-latent-rheumatic-heart-disease-100478050","NCT05504928","Effectiveness of a School-centered Prevention Program on Prevalence of Latent Rheumatic Heart Disease","Effectiveness of a School-centered Primary and Secondary Prevention Program on Prevalence of Latent Rheumatic Heart Disease","NEPAL4","Inclusion Criteria:\n\n* Age 5-16 years\n* Attending Tulsi Secondary Boarding School in Tulsipur, Nepal.\n\nExclusion Criteria:\n\n* Children \u002F primary caregivers not providing informed consent to participate\n* Children not attending Tulsi Secondary Boarding School in Tulsipur.",{"count":135,"type":19},2300,[69],"The overall objective is to evaluate the effectiveness of a school-centered primary and secondary prevention program on the prevalence of latent rheumatic heart disease among schoolchildren in Nepal, and to investigate the role of socioeconomic and environmental factors in the development and progression of rheumatic heart disease.",[106,23],[106,140,141,142],"Primary Prevention","Secondary Prevention","Screening","2022-08-15",{"date":145,"type":33},"2022-08-17",{"date":147,"type":33},"2022-06-01",{"date":149,"type":19},"2026-12-01",{"name":151,"class":40},"Insel Gruppe AG, University Hospital Bern"]